Blog
RSS FeedPosted by Michael Wonder on 13 Oct 2020
Top Democrats call for watchdog to review Trump Medicare drug cards
13 October 2020 - Top-ranking Democrats want an independent watchdog to expedite a review of the Trump administration's plans to ...
Posted by Michael Wonder on 12 Oct 2020
Inventiva receives FDA breakthrough therapy designation for lead drug candidate lanifibranor in NASH
12 October 2020 - Inventiva today announced that the U.S. FDA has granted breakthrough therapy designation to lanifibranor, the Company’s lead ...
Posted by Michael Wonder on 05 Oct 2020
Real world evidence from a narrow therapeutic index product (levothyroxine) reflects the therapeutic equivalence of generic drug product
5 October 2020 - The National Institute of Diabetes and Digestive and Kidney Diseases reports that almost 5% of the U.S. ...
Posted by Michael Wonder on 25 Sep 2020
Innova Therapeutics receives rare paediatric disease designation from the FDA for IVT-8086 for the treatment of osteosarcoma
24 September 2020 - Innova Therapeutics Inc., a biopharmaceutical company committed to developing innovative cancer therapies for patients who have inadequate ...
Posted by Michael Wonder on 23 Sep 2020
Medicare wouldn’t cover costs of administering coronavirus vaccine approved under Emergency Use Authorisation
21 September 2020 - Trump administration officials are exploring options to quickly fix plan to make the vaccine free for all ...
Posted by Michael Wonder on 22 Sep 2020
New early scientific advice service to support medicine registrations
22 September 2020 - The Therapeutic Goods Administration has launched a new initiative - the Early Scientific Advice service - ...
Posted by Michael Wonder on 03 Sep 2020
CMS grants additional reimbursement for the Eluvia drug eluting vascular stent system
3 September 2020 - Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a new technology add-on ...
Posted by Michael Wonder on 20 Aug 2020
EMA agrees to review UCB's bimekizumab
18 August 2020 - Information about marketing authorisation application to EMA not yet disclosed by UCB. ...
Posted by Michael Wonder on 03 Aug 2020
Medicare Part D plans rarely cover brand name drugs when generics are available
3 August 2020 - Study examines Medicare Part D coverage to quantify how often brand-name drugs are designated preferred over generics. ...
Posted by Michael Wonder on 07 Jul 2020
Use of infliximab biosimilar in Medicare population is low but growing
7 July 2020 - Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the ...
Posted by Michael Wonder on 07 Jul 2020
Abandoning list prices in Medicaid drug reimbursement did not affect spending
7 July 2020 - State fee-for-service Medicaid programs have traditionally based payments to pharmacies for drugs on a percentage of the ...
Posted by Michael Wonder on 06 Jul 2020
CMS’s proposed Medicaid best price loophole for value based purchasing of drugs
6 July 2020 - For three decades, US pharmaceutical companies have agreed to sell their products to Medicaid programs at ...
Posted by Michael Wonder on 28 Jun 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances
25 June 2020 - Products which received conditional marketing authorisation or authorisation in exceptional circumstances by European Medicines Agency up to ...
Posted by Michael Wonder on 25 Jun 2020
Federal prosecutors allege Regeneron used a charity to pay kickbacks to Medicare patients
24 June 2020 - Federal officials on Wednesday alleged that Regeneron Pharmaceuticals donated tens of millions of dollars to a ...
Posted by Michael Wonder on 23 Jun 2020
MHRA extends access to Santhera's DMD drug via the EAMS
23 June 2020 - The UK’s Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early ...